Independent
Tenure on this board
5.0 yrs
Also a director at
Beone Medicines Ltd (ONC)Bicycle Therapeutics PLC (BCYC)
2 nominees · 4 ballot items.
Elect two Class II directors; ratify Ernst & Young LLP as independent auditors for 2026; approve an amendment to the Certificate of Incorporation to increase authorized common shares from 300,000,000 to 450,000,000; and approve adjournment of the meeting if there are insufficient votes to approve the charter amendment.
Elect Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. as Class II directors to serve three-year terms expiring in 2029.
Ratify the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Approve an amendment to the Second Amended and Restated Certificate of Incorporation to increase authorized common shares from 300,000,000 to 450,000,000.
This management proposal asks shareholders to approve a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock from 300 million to 450 million. Management and the Board argue that the additional authorized shares will provide flexibility to raise capital, pursue business combinations, grant equity incentives and respond to market opportunities promptly without the delay and expense of convening a special meeting. The filing notes existing outstanding instruments (common shares, warrants, options and plan reserves) and frames the amendment as a tool to preserve the Company’s ability to execute financing and strategic transactions and to attract and retain talent through equity compensation. Management acknowledges that the amendment itself will not immediately dilute existing holders, but warns that future issuances could dilute earnings per share, voting power and book value per share and that abstentions/broker non-votes will effectively vote against the proposal. The disclosure also addresses and characterizes potential anti-takeover effects: while not intended as an anti-takeover measure, increasing authorized shares could be used to frustrate takeovers or dilute bidders, and the Company notes it has no current plan to use the amendment for that purpose. The Board reserves the right to abandon the amendment even if approved and explains that approval requires a majority of all issued and outstanding shares. From an investor analysis perspective, the proposal creates optionality for management to finance or execute strategic transactions quickly but introduces the risk of dilution and potential governance implications if shares are issued opportunistically. The proposal should be evaluated against the Company’s near-term capital needs, existing investors’ holdings and any contractual limitations (such as beneficial ownership caps on certain holders) that may constrain immediate large-scale issuances.
Authorize the meeting to be adjourned, if necessary, to permit additional solicitation of proxies to obtain approval of the Charter Amendment (Proposal 3).
This management proposal asks shareholders to authorize the presiding officer to adjourn the Annual Meeting, if necessary, to allow additional solicitation of proxies to obtain approval of Proposal 3 (the Charter Amendment). The adjournment mechanism is a common contingency used when a transaction or charter change requires a higher vote threshold or broad shareholder support and the initial vote is insufficient. Management frames this as a procedural measure to permit continued proxy solicitation without reconvening an entirely new meeting, noting that notices will be provided if an adjournment exceeds thirty days. The proxy language also expressly authorizes successive adjournments, which could allow multiple rounds of solicitation. For investors, this measure can preserve management’s ability to seek shareholder approval without immediate abandonment of the Charter Amendment but also allows the Board to use more time to persuade holders, which may include targeted outreach to large holders and brokers. The adjournment proposal has minimal direct economic effect on shareholders by itself but is materially linked to Proposal 3; adoption of this proposal increases the practical likelihood that the Board can obtain the votes necessary to effect the amendment. Governance considerations include the potential for delay and the use of company resources for further solicitation; shareholders should weigh the procedural convenience against the substantive impacts of Proposal 3.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9.84% | 17,754,430 | $40M |
| 2 | TCG Crossover Management, LLC | 9.84% | 17,754,430 | $39M |
| 3 | Versant Venture Management, LLC | 6.75% | 12,166,109 | $27M |
| 4 | Deep Track Capital, LP | 5.26% | 9,487,745 | $21M |
| 5 | RTW INVESTMENTS, LP | 4.82% | 8,695,652 | $20M |
| 6 | Commodore Capital LP | 4.82% | 8,695,652 | $20M |
| 7 | Venrock Adviser, LLC | 4.82% | 8,695,652 | $20M |
| 8 | Point72 Asset Management, L.P.Activist | 3.31% | 5,964,678 | $13M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.15% | 5,686,204 | $13M |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 2.78% | 5,017,733 | $11M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.